{"transactions":[{"id":683655,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-08-18T21:51:24.000Z","date":"2026-08-17","kind":"sale","planned":false,"acquired":false,"shares":2230,"price":1.93,"value":4303.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026."}],"balance_after":294379,"source":{"system":"sec-edgar","filing":"0001193125-26-355764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526355764/ownership.xml","form_type":"4"}},{"id":830857,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-03-23T20:05:08.000Z","date":"2026-03-19","kind":"sale","planned":false,"acquired":false,"shares":12311,"price":2.17,"value":26714.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units."}],"balance_after":293609,"source":{"system":"sec-edgar","filing":"0001193125-26-119705","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526119705/ownership.xml","form_type":"4"}},{"id":893521,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-02-20T02:02:25.000Z","date":"2026-02-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":2201,"price":2.27,"value":4996.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2025."}],"balance_after":305920,"source":{"system":"sec-edgar","filing":"0001193125-26-060037","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526060037/ownership.xml","form_type":"4"}},{"id":929045,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2026-01-28T21:30:02.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":912000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026."}],"balance_after":912000,"derivative":{"exercise_price":1.48,"expiration_date":"2036-01-25","underlying":"Common Stock","underlying_shares":912000},"source":{"system":"sec-edgar","filing":"0001193125-26-027287","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526027287/ownership.xml","form_type":"4"}},{"id":1017642,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-10-16T20:01:06.000Z","date":"2025-10-14","kind":"grant","planned":false,"acquired":true,"shares":597500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026."}],"balance_after":597500,"derivative":{"exercise_price":1.7,"expiration_date":"2035-10-14","underlying":"Common Stock","underlying_shares":597500},"source":{"system":"sec-edgar","filing":"0001193125-25-241381","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312525241381/ownership.xml","form_type":"4"}},{"id":1036390,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-09-18T20:23:19.000Z","date":"2025-09-17","kind":"purchase","planned":false,"acquired":true,"shares":71163,"price":1.0805,"value":76891.6215,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.09, inclusive."}],"balance_after":305121,"source":{"system":"sec-edgar","filing":"0001193125-25-207432","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312525207432/ownership.xml","form_type":"4"}},{"id":1036389,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-09-18T20:23:19.000Z","date":"2025-09-16","kind":"purchase","planned":false,"acquired":true,"shares":21070,"price":1.066,"value":22460.62,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4."}],"balance_after":233958,"source":{"system":"sec-edgar","filing":"0001193125-25-207432","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312525207432/ownership.xml","form_type":"4"}},{"id":1061945,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-08-19T20:09:59.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":2382,"price":0.6404,"value":1525.4328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.64 to $0.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2025."}],"balance_after":212888,"source":{"system":"sec-edgar","filing":"0000950170-25-110099","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025110099/ownership.xml","form_type":"4"}},{"id":1171871,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-15T20:14:02.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares subject to the option vest on April 11, 2026."}],"balance_after":125000,"derivative":{"exercise_price":0.49,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-010686","document":"form4-04152025_080459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925010686/form4-04152025_080459.xml","form_type":"4"}},{"id":1200156,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-03-18T20:41:30.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026."}],"balance_after":212270,"source":{"system":"sec-edgar","filing":"0001415889-25-008417","document":"form4-03182025_080326.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925008417/form4-03182025_080326.xml","form_type":"4"}},{"id":1253105,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-02-21T21:20:19.000Z","date":"2025-02-19","kind":"sale","planned":false,"acquired":false,"shares":2159,"price":1.1502,"value":2483.2818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2024."}],"balance_after":170270,"source":{"system":"sec-edgar","filing":"0001415889-25-005067","document":"form4-02212025_090215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925005067/form4-02212025_090215.xml","form_type":"4"}},{"id":1296453,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-23T23:07:03.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":478000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025."}],"balance_after":478000,"derivative":{"exercise_price":1.65,"expiration_date":"2035-01-20","underlying":"Common Stock","underlying_shares":478000},"source":{"system":"sec-edgar","filing":"0001415889-25-001959","document":"form4-01232025_110159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588925001959/form4-01232025_110159.xml","form_type":"4"}},{"id":1343120,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-04T21:13:02.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 30 equal monthly installments beginning on January 2, 2025."}],"balance_after":200000,"derivative":{"exercise_price":1.66,"expiration_date":"2031-12-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-028239","document":"form4-12042024_091258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924028239/form4-12042024_091258.xml","form_type":"4"}},{"id":1431428,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-08-16T21:05:34.000Z","date":"2024-08-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":2191,"price":2.58,"value":5652.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs."}],"balance_after":169429,"source":{"system":"sec-edgar","filing":"0001415889-24-021471","document":"form4-08162024_090831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924021471/form4-08162024_090831.xml","form_type":"4"}},{"id":1572540,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-03-18T20:06:28.000Z","date":"2024-03-14","kind":"purchase","planned":false,"acquired":true,"shares":4400,"price":11.3117,"value":49771.48,"ownership":{"direct":true},"balance_after":171620,"source":{"system":"sec-edgar","filing":"0001415889-24-008260","document":"form4-03182024_080318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924008260/form4-03182024_080318.xml","form_type":"4"}},{"id":1638469,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option","published_at":"2024-02-16T23:03:55.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest in 48 equal monthly installments beginning on March 14, 2024."}],"balance_after":190000,"derivative":{"exercise_price":15.84,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001415889-24-004210","document":"form4-02162024_110246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924004210/form4-02162024_110246.xml","form_type":"4"}},{"id":1638468,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2024-02-16T23:03:55.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on August 14, 2024."}],"balance_after":167220,"source":{"system":"sec-edgar","filing":"0001415889-24-004210","document":"form4-02162024_110246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000141588924004210/form4-02162024_110246.xml","form_type":"4"}},{"id":1783029,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-09-12T20:24:52.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the option vest on September 5, 2024 and 1/48th of the shares vest monthly thereafter."}],"balance_after":1200000,"derivative":{"exercise_price":4.92,"expiration_date":"2033-09-07","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001209191-23-049102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919123049102/doc4.xml","form_type":"4"}},{"id":1846616,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-06-22T20:46:53.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":20200,"derivative":{"exercise_price":8.14,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001209191-23-039103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919123039103/doc4.xml","form_type":"4"}},{"id":2230119,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock (right to buy)","published_at":"2022-06-17T00:26:50.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":12004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":12004,"derivative":{"exercise_price":6.67,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":12004},"source":{"system":"sec-edgar","filing":"0001209191-22-037645","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919122037645/doc4.xml","form_type":"4"}},{"id":2471747,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":60,"price":30.23,"value":1813.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":285956,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471746,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":440,"price":30.23,"value":13301.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 to $30.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2097326,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471745,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":181,"price":29.6,"value":5357.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":286016,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471744,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":1329,"price":29.6,"value":39338.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2097766,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471743,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":299,"price":28.37,"value":8482.63,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":286197,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471742,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":2196,"price":28.37,"value":62300.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.01 to $28.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2099095,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471741,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":1296,"price":27.49,"value":35627.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":286496,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471740,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":286496,"price":27.49,"value":7875775.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2101291,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471739,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":2339,"price":26.48,"value":61936.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":287792,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471738,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":17169,"price":26.48,"value":454635.12,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2110800,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471737,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":1627,"price":25.29,"value":41146.83,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":290131,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2471736,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-16T02:48:32.000Z","date":"2021-12-13","kind":"sale","acquired":false,"shares":11945,"price":25.29,"value":302089.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2127969,"source":{"system":"sec-edgar","filing":"0000899243-21-048463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924321048463/doc4.xml","form_type":"4"}},{"id":2477405,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":12,"price":32.16,"value":385.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":291758,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477404,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":88,"price":32.16,"value":2830.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2139914,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477403,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":2172,"price":31.55,"value":68526.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $32.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":291770,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477402,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":15942,"price":31.55,"value":502970.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $32.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2140002,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477401,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":967,"price":30.77,"value":29754.59,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.12 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":293942,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477400,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-10","kind":"sale","acquired":false,"shares":7093,"price":30.77,"value":218251.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.12 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2155944,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477399,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":1911,"price":32.73,"value":62547.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":294909,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477398,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":14028,"price":32.73,"value":459136.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2163037,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477397,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":5751,"price":32.06,"value":184377.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":296820,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477396,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":42203,"price":32.06,"value":1353028.18,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2177065,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477395,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":1560,"price":31.08,"value":48484.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":302571,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477394,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":11452,"price":31.08,"value":355928.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2219268,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477393,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":208,"price":33.8,"value":7030.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $33.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":304131,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477392,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":1531,"price":33.8,"value":51747.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $33.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2230720,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477391,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":4883,"price":33.23,"value":162262.09,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":304339,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2477390,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-11T02:22:42.000Z","date":"2021-12-08","kind":"sale","acquired":false,"shares":35836,"price":33.23,"value":1190830.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2232251,"source":{"system":"sec-edgar","filing":"0001209191-21-069154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121069154/doc4.xml","form_type":"4"}},{"id":2668642,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:54:16.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":12004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders."}],"balance_after":12004,"derivative":{"exercise_price":59.66,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":12004},"source":{"system":"sec-edgar","filing":"0001209191-21-040728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000120919121040728/doc4.xml","form_type":"4"}},{"id":3078917,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":38660,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":38660},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078916,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":664660,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":664660},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078915,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":18705,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18705},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078914,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":137286,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":137286},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078913,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":10529,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10529},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078912,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":11110,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11110},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078911,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":150801,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150801},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078910,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":8175,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8175},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078909,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":59998,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":59998},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078908,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":39758,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":39758},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078907,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":683523,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":683523},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078906,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":222752,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":222752},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078905,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":1633743,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1633743},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078904,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":78175,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78175},"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078903,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":111528,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F12","text":"Includes 8,684 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":120212,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078902,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":22000,"price":19,"value":418000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held of record by Lightstone Ventures II(A), LP (LV II(A) LP). As a managing director of LSV Associates II, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078901,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":1498984,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes 146,485 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2023469,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078900,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":378000,"price":19,"value":7182000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held of record by Lightstone Ventures II, LP (LV II LP). As a managing director of LSV Associates II, LLC (LSV Associates II), the General Partner of LV II LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LV II LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":378000,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078899,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":249632,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 59,590 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by shares held of record by Lightstone Ventures (A), LP (LV(A) LP) for which LSV Associates is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV(A) LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":309222,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078898,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":1831027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 437,060 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held of record by shares held of record by Lightstone Ventures, LP (LV LP) for which LSV Associates, LLC (LSV Associates) is the General Partner. The reporting person shares voting and dispositive power with respect to the shares held of record by LV LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein."}],"balance_after":2268087,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3078897,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-22T01:31:06.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":88704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 18,516 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020."}],"balance_after":107220,"source":{"system":"sec-edgar","filing":"0000899243-20-019931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019931/doc4.xml","form_type":"4"}},{"id":3080675,"issuer":{"id":6040,"kind":"organization","name":"ALX ONCOLOGY HOLDINGS INC"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T23:06:50.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":24009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020."}],"balance_after":24009,"derivative":{"exercise_price":19,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":24009},"source":{"system":"sec-edgar","filing":"0000899243-20-019579","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810182/000089924320019579/doc4.xml","form_type":"4"}},{"id":4274656,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Options to Purchase Common Stock","published_at":"2017-06-22T23:41:41.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 20, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 20, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reporting person is a member of Morgenthaler Advisors IX, LLC (\"MA IX\"), which is the investment adviser of Morgenthaler Venture Partners IX, LP (\"MVP IX\"). Pursuant to the limited partnership agreement of MVP IX and the limited liability company agreement of MA IX, the reporting person is deemed to hold the option for the benefit of MVP IX. Upon exercise of the option, the shares will be transferred to MA IX, and the value of such shares will reduce the management fees payable to MA IX by MVP IX. As such, MVP IX is entitled to the economic benefits of the option and the reporting person disclaims beneficial ownership of the option."}],"balance_after":15000,"derivative":{"exercise_price":22.37,"expiration_date":"2027-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-17-041012","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465917041012/a4.xml","form_type":"4"}},{"id":4572022,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":481503,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Lightstone Ventures (A), L.P.  LSV GP is the General Partner of Lightstone Ventures (A), L.P. (\"LSV-A\").  LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68786},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572021,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":3533875,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. (\"LSV\"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":504839},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572020,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":517617,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Lightstone Ventures (A), L.P.  LSV GP is the General Partner of Lightstone Ventures (A), L.P. (\"LSV-A\").  LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73945},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572019,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":3798914,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. (\"LSV\"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":542702},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572018,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-2 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":3408439,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":486919},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572017,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":3664071,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":523438},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572016,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":false,"shares":9744916,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1392130},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572015,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"other","acquired":false,"shares":63019,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2022-04-01","underlying":"Common Stock","underlying_shares":63019},"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572014,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"purchase","acquired":true,"shares":15633,"price":13,"value":203229.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Lightstone Ventures (A), L.P.  LSV GP is the General Partner of Lightstone Ventures (A), L.P. (\"LSV-A\").  LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein."}],"balance_after":4066503,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572013,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"purchase","acquired":true,"shares":114752,"price":13,"value":1491776.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. (\"LSV\"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein."}],"balance_after":4050870,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572012,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"purchase","acquired":true,"shares":263538,"price":13,"value":3425994.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":3936118,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572011,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":68786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Lightstone Ventures (A), L.P.  LSV GP is the General Partner of Lightstone Ventures (A), L.P. (\"LSV-A\").  LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein."}],"balance_after":3672580,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572010,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":504839,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. (\"LSV\"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein."}],"balance_after":3603794,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572009,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":73945,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by Lightstone Ventures (A), L.P.  LSV GP is the General Partner of Lightstone Ventures (A), L.P. (\"LSV-A\").  LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV-A except to the extent of their pecuniary interest therein."}],"balance_after":3098955,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572008,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":542702,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by Lightstone Ventures, L.P. LSV Associates, LLC, or LSV GP, is the General Partner of Lightstone Ventures, L.P. (\"LSV\"). LSV GP and the managing directors of LSV GP disclaim beneficial ownership of the shares held by LSV except to the extent of their pecuniary interest therein."}],"balance_after":3025010,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572007,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":486919,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":2482308,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572006,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":523438,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":1995389,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572005,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"exercise","acquired":true,"shares":1392130,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Series A Preferred Stock converted into Common Stock on a 1-for-7 basis automatically and without additional consideration upon the closing of the Issuer's initial public offering, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":1471951,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572004,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"sale","acquired":false,"shares":340,"price":13,"value":4420.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":79821,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}},{"id":4572003,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":22280,"kind":"person","name":"Lettmann Jason","position":1,"cik":"0001688269","reported_name":"Lettmann Jason","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T20:51:14.000Z","date":"2016-10-31","kind":"other","acquired":true,"shares":63019,"price":0.07,"value":4411.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 340 of the warrant shares to pay the aggregate exercise price, using the offering price in the Issuer's initial public offering of $13.00, and issuing to the reporting person the remaining 62,679 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Morgenthaler Venture Partners IX, L.P. (\"MVP IX\"). The general partner of MVP IX is Morgenthaler Management Partners IX, LLC (\"MMP IX\"). MMP IX may be deemed to indirectly beneficially own the securities directly held by MVP IX.  Jason Lettmann, a director of the Issuer, is a Member of MMP IX and as such, shares voting and investment power over the securities directly held by MVP IX.  MMP IX and Jason Lettmann disclaim beneficial ownership of the securities held by MVP IX except to the extent of their respective pecuniary interests therein."}],"balance_after":80161,"source":{"system":"sec-edgar","filing":"0001104659-16-153348","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688269/000110465916153348/a4.xml","form_type":"4"}}]}